ELRIG UK and British Pharmacological Society have appointed Dr. Ann Hayes to chair joint steering committee

Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community

5 Feb 2020
Diane Li
Assistant Editor

Industry news

The European Laboratory Research & Innovation Group UK and the British Pharmacological Society have announced that Dr. Ann Hayes has been selected to chair their joint steering committee. Dr. Hayes will lead the committee to help ensure both organizations meet the objectives of the newly formed strategic alliance, which aims to bring new opportunities for education and networking in UK drug discovery and pharmacology.

Dr. Ann Hayes is a well-respected member of the drug discovery and pharmacology community with expertise in central nervous system disorders. She has co-founded three drug discovery companies, and sits on the scientific advisory boards of several others. Dr. Hayes has been a trustee of the British Pharmacological Society, and chaired the industry sub-committee from 2012 to 2015. Prior to this, she spent over 20 years in senior roles at Glaxo (then Glaxo Wellcome), most recently as the Director of Discovery Portfolio. She completed her Ph.D. in Pharmacology at the School of Pharmacy in London.

Dr. Del Trezise, ELRIG UK member of the joint steering committee, said: “Dr. Hayes’ experience in pharmacology and drug discovery means she is ideally placed to bring together ideas from these complementary fields, helping ELRIG UK and the British Pharmacological Society reach a broad scientific audience.”

Professor Clive Page, President Elect of the British Pharmacological Society and member of the joint steering committee, added: “We look forward to working closely with Dr. Hayes to guide our strategic direction. This collaboration marks a new chapter of our history championing innovation in the life sciences and pharmacology.”

Dr. Ann Hayes, Chair of the joint steering committee, commented: “I am honored to be steering both organizations during our partnership. I will work hard with the committee to ensure we can meet our joint aims as organizations: to develop new openings for scientific exchange and collaboration, and to help drive the successful discovery and development of new medicines across the UK.”

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.PharmaceuticalsPharmaceuticals are medicinal drugs used in healthcare to diagnose, prevent, cure and treat illnesses. Pharmaceuticals that are excreted after use appear in wastewater and can have detrimental effects on the environment.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Drug Discovery & Development Screening